4526
RIKEN VITAMIN CO.,LTD.
理研ビタミン
- Industry
- Foods
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2022
79,231
Mar 2023
88,750
Mar 2024
91,484
Mar 2025
95,582
Mar 2026
96,300
Operating profit(million JPY)
Mar 2022
5,840
Mar 2023
7,158
Mar 2024
9,371
Mar 2025
8,724
Mar 2026
6,900
Operating profit margin(%)
Mar 2022
7.37
Mar 2023
8.07
Mar 2024
10.24
Mar 2025
9.13
Mar 2026
7.17
Profit before tax(million JPY)
Mar 2022
20,313
Mar 2023
7,857
Mar 2024
11,909
Mar 2025
12,706
Mar 2026
10,244
Profit(million JPY)
Mar 2022
21,582
Mar 2023
6,414
Mar 2024
8,755
Mar 2025
9,388
Mar 2026
7,035
Total assets(million JPY)
Mar 2022
102,660
Mar 2023
105,223
Mar 2024
118,776
Mar 2025
112,999
Mar 2026
116,387
Cash and cash equivalents(million JPY)
Mar 2022
15,064
Mar 2023
16,656
Mar 2024
20,141
Mar 2025
18,835
Mar 2026
19,131
Cash flows from operating activities(million JPY)
Mar 2022
6,823
Mar 2023
7,835
Mar 2024
10,451
Mar 2025
7,892
Mar 2026
5,963
Cash flows from investing activities(million JPY)
Mar 2022
-3,661
Mar 2023
-2,034
Mar 2024
-554
Mar 2025
353
Mar 2026
1,747
Cash flows from financing activities(million JPY)
Mar 2022
-7,565
Mar 2023
-4,578
Mar 2024
-7,084
Mar 2025
-9,965
Mar 2026
-8,040
Return on equity(%)
Mar 2022
38.3
Mar 2023
9.3
Mar 2024
11.8
Mar 2025
12.1
Mar 2026
8.7
Equity ratio(%)
Mar 2022
64.8
Mar 2023
67.8
Mar 2024
64.5
Mar 2025
70.1
Mar 2026
71.6
Earnings per share(JPY per share)
Mar 2022
657.98
Mar 2023
195.51
Mar 2024
268.44
Mar 2025
310.08
Mar 2026
238.19
Net assets per share(JPY per share)
Mar 2022
2,027.84
Mar 2023
2,174.39
Mar 2024
2,523.84
Mar 2025
2,649.95
Mar 2026
2,855.29
Dividend per share(JPY per share)
Mar 2022
46
Mar 2023
59
Mar 2024
81
Mar 2025
94
Mar 2026
110
Payout ratio(%)
Mar 2022
6.99
Mar 2023
30.18
Mar 2024
30.17
Mar 2025
30.31
Mar 2026
46.18
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.